 If progression in neuropathy as indicated by an increase in the Neuropathy Impairment Score NIS of greater than or equal to 10 or a modified Rankin Score increase of 1 grade the patient was off study. In addition, if the subject elected to pursue other active treatment including but not limited to plasmapheresis, high-dose intravenous immuneglobulin IVIG, chemotherapeutic agents, or high dose corticosteroids, or if conditions in the exclusion criteria develop subsequent to enrollment, the subject was off study. 